Life Sciences Archive » January, 2012

Life Sciences - January, 2012

198 articles

• Chile Fines 2 Pharmacy Chains $38M For Price Fixing
• Micromet Investor Sues To Halt $1.2B Amgen Purchase
• Generic Cancer Drug MDL Tossed In Light Of Mensing
• Winthrop & Weinstine Snares 6 Dorsey & Whitney IP Attys
• Omnicare Faces OT Class Action By Technicians, Others
• Enzo, Roche Square Off Over Medical Testing Patent
• Cadwalader Aids AngioDynamics In $372M Device Maker Buy
• Bayer Seeks to Block Pfizer's Bovine Drug With IP Suit
• Warner Chilcott Targeted Over Sales Reps' OT Pay
• Allergan, Merz Row Over Botox Secrets Headed To Trial
• Pfizer Wants Court To Pause Zoloft Birth Defects Suit
• AstraZeneca Sues Generics Maker Over Nexium Patents
• FDA Accused Of Spying On Employee Scientists' Emails
• Ex-Symmetry Medical Workers Consent To Fraud Claims
• J&J, Merck Take Heat Over L'Oreal Sunscreen Patents
• Drug Co. Valeant Walks Away From Bid for Ista
• Kilpatrick Brings Finnegan IP Whiz To Silicon Valley
• FTC Sues Omnicare To Block $441M PharMerica Merger
• Teva Unit Recalls Cancer Drug Treanda Over Glass Fragments
• Allergan Targets Hi-Tech Over IP For Glaucoma Generic
• FDA Reopens Comments On Drug Ad Rule In New Study's Wake
• Medtronic Hit With $10M Jury Verdict Over Catheter Patent
• Cooley Partner Takes GC Job At Jazz Pharmaceuticals
• BPA Class Certification: Denied
• Insurance Watchdog Investigating Lap-Band Centers: Aetna
• 5 Ways To Ramp Up Your Patent Portfolio
• EC Proceeds With Antitrust Probe Of French Drug Co.
• Jury Finds Varian Willfully Infringed Cancer Patent
• Affymetrix Suit Over Illumina Microarray IP Reopened
• AstraZeneca, Lupin Soothe Nexium Patent Fight
• Cordis Sues USPTO For Blocking Stent Re-Exam Subpoenas
• Pfizer Faces ERISA Stock-Drop Suit By Puerto Rico Workers
• Kreos Secures $160M For European Growth Fund
• Nestle Fires Back At Mead Johnson Over Bottle Design IP
• Graceway's Ch. 11 Plan Hinges On Asset Sale
• Celgene Snags Cancer Treatment Co. Avila For $350M
• Illumina Rebuffs $5.7B Roche Bid With Poison Pill
• Fed. Circ. Lifts Block On Generic Lovenox Sales
• A Health And Welfare Benefit Year In Review
• Ranbaxy Bows To Sweeping Penalties From US
• Sullivan Helps Amgen In $1.2B Micromet Buy
• Founder Of French Silicon Implant Co. Arrested Amid Scandal
• Forest Labs Bribed Study Authors To Boost Celexa: Suit
• Biotech Co. Affymetrix Pays $96M To End Investor Suit
• 4th Circ. Tosses Suit Over FDA-Approved Medtronic Device
• Cephalon Sues Mylan, Sandoz Again Over Generic Fentora
• Celgene, Novartis Chastised Over Cancer Drug Claims
• CPSC Proposes Child-Resistant Packages for Decongestants
• Covidien Makes Deal With Watson To Allow Generic Exalgo
• Takeda Hid Gout, GERD Drug Interactions: Whistleblower
• House Bill Targets High Court's Eminent Domain Ruling
• Forest Labs Derivative Suit Belongs In Federal Court: Atty
• Biosimilars Law In Limbo
• Substantial Guidance For The FDA's 510(k) Program
• Roche Launches $5.7B Hostile Bid For Illumina
• Pfizer Triumphs Over Drinkmaker In Viagra Mark Dustup
• Novartis To Settle Sales Reps' OT Claims For $99M
• Canada, Novartis Issue Warning On Blood Pressure Drugs
• Health Group Of The Year: Weil Gotshal & Manges
• APP Settles Patent Row Over Generic Blood Thinner
• EU Lawmakers Call For Tighter Controls On Breast Implants
• Bradley Arant Nabs Winston & Strawn Antitrust Atty
• Acura Settles Shareholder Claims Over Acurox For $1.5M
• Generics Cos. Fight Lovenox Injunction In Fed. Circ.
• Class Squashed In Beetle-Tainted Baby Formula Action
• Drug Co. Watson Grows Asian Presence With Ascent Buy
• Ex-McKinsey Exec's $40M Suit Against Fund Tossed
• CR Bard, Others Face Onslaught Of Surgical Mesh Suits
• St. Jude Awarded $27M In Vascular Closure Device IP Fight
• Venable Lures 3 IP Experts From Patton Boggs
• Lilly Sues Accord Over Generic Lung Cancer Drug Alimta
• Abbott Sues Generic Maker Over Cholesterol Drug Patent
• Health Group Of The Year: Ropes & Gray
• FDA Delays Decision on Alexza Antipsychotic Treatment
• Sandoz Targeted Over Generic Cancer Drug Fusilev
• FTC To Drop Antitrust Suit Over Lundbeck Heart Defect Drug
• FDA Panel Turns Down Columbia, Watson Preterm Birth Gel
• Proskauer Malpractice Suit Not Time-Barred: J&J Heir
• Meda Sues 2 Cos. Over Generic Nasal Spray Patent
• Wyeth, Cordis Stent Patents Are Invalid, Judge Says
• Health Group Of The Year: Covington & Burling
• Braintree, Buyers Settle Generic MiraLax Suit For $17M
• Dems Seek Probe Of Medical Device Cos.
• 11 Deaths Prompt EU Review Of Novartis Drug Gilenya
• Expert Testimony OK In Miscarriage Drug Suit: Judge
• Merck Unit, Pamlab Sue Over Generic Metafolin
• Health Care Group Of The Year: Arnold & Porter
• Charges Against Stryker, Sales Staff Dropped For $15M
• FDA Seeks More Info On Bristol, AstraZeneca Diabetes Drug
• Merck Closes Out Canadian Vioxx Claims For Up To $36.5M
• 4th Circ. Upholds GSK Win In Vaccine Contract Suit
• The Lowdown On Top Up Options
• Pfizer Seeks To Merge 59 Zoloft Birth Defect Suits
• J&J Settles Texas' Risperdal Suit For $158M
• Alnylam Claims Tekmira Infringed RNAi Tech Patents
• Covidien Recalls Chest Surgery Device After Patient Deaths
• 2nd Circ. Gave Undue FLSA Deference: NYC To High Court
• Feds Push For 1st Circ. To Reopen FCA Suit Against Pfizer
• Latham Woos Pharma IP Pro From Wilson Sonsini
• Stiefel Can't Shake ERISA, Fraud Claims Over GSK Buy
• Health Group Of The Year: Akin Gump
• Stryker To Pay $15M To End False Marketing Case
• Baker Botts Lures McDermott M&A Pros To Calif. Digs
• Cadwalader Scores Top Dealmaker From Cahill Gordon
• Asian Buyout Firm Takes $100M Stake In DM Healthcare
• 2nd Circ. Quashes Savient Investor's Class Action
• GSK Settles Bulk Of Avandia MDL Cases
• Ropes & Gray Can't Shake Patent Malpractice Suit
• Feds Drop Charges Against Stryker Sales Manager
• Ex-Sanofi Researcher Cops To Trade Secrets Theft
• FDA Fines Red Cross $9.6M For Continued Missteps
• Fresenius Targets Nostrum's Generic PhosLo GelCaps
• The FDA Crackdown On Health Care Provider Ads
• Merck Unit Sues To Block Teva's Generic Singulair
• Brain Infection Reports Prompt Boxed Warning On Adcetris
• The 10 Worst Drug/Medical Device Decisions Of 2011
• Fighting The Scourge Of Corruption
• McKesson's Bid To Revive Pill Dispenser IP Suit Nixed
• Lilly, 3rd-Party Payors Reach $4.5M Deal In Zyprexa Case
• Stryker Unit Settles Bone Staple Patent Suit
• Inhibitex Investor Sues To Block $2.5B Bristol-Myers Deal
• CVS To Pay $5M To End FTC's Deceptive Drug Price Claims
• Atty Accused Of Defaming 3M Asks To Toss Case
• Insurer Tries To Dodge Defending Avastin Distributor
• ITC Staff Sides With Merck In NuvaRing Patent Battle
• Walgreen, Par Schemed To Overcharge For Generics: Suit
• Meritain Accuses Express Scripts Of Client Data Theft
• More Countries Raise Alarm Over Faulty Breast Implants
• Perrigo Beats Reckitt Unit's Suit Over Generic Mucinex
• FDA Warns J&J Unit Over Insulin Pump Reporting Delays
• Clifford Chance Scores 2 Dewey & LeBoeuf M&A Pros
• Medtronic Asks Fed. Circ. To Nix Edwards' $74M IP Award
• Yellow Wood Unveils $225M Fund With Ropes & Gray's Help
• Novo Pays PE Firm $708M For Stake In Chr. Hansen
• Flagship Ventures Nets $270M For 4th VC Fund
• FDA Advisers On Yaz Had Ties To Bayer: Ex-Agency Chief
• Consumers Renew $29B Express Scripts, Medco Deal Fight
• FDA's Social Media Guidance Skirts Questions Of Liability
• CooperVision Hit With Investor Suit Over Lens Recall
• Boehringer Blood Thinner Linked To Heart Attacks: Study
• Vytorin Derivative Suit Settlement Wins Initial Nod
• Judge Severs Charges Against Former Stryker Head
• Calif. County's Sherman Act Claim Nixed In Plasma MDL
• Weil Reps Sanofi On $125M Biotech Venture With VCs
• Partnering With The Feds For IP Enforcement: Part 1
• Shire Hits Sandoz With 2nd Suit Over Generic Intuniv
• Conceptus Loses Injunction Bid In Contraceptive IP Fight
• Fed. Circ. Upholds Life Tech Injunction In Cell Patent Row
• Novartis Issues $120M Drug Recall, Plant Suspension
• Stryker Must Face Suit Over Joint Pain Pumps: Judge
• Bryan Cave Helps Sigma-Aldrich In $350M Deal
• SK Capital, IBA To Form $229M Medical Imaging Venture
• Drugmaker Valeant Losing Patience In $327M Hostile Bid
• Small Business Group Tells SEC To Relax Regulations
• Rite Aid Overcharges Drug Discount Plan Members: Suit
• Aisling Capital, Others Inject $48M Into Roka Bioscience
• CVS Pharmacists Dispense Wage Suit Over Travel Pay
• Philips Slaps Rival With New Defibrillator Patent Suit
• Vioxx MDL Attys Shut Out Of $950M DOJ Settlement
• Knowledge Is Power In Failure-To-Warn Claims
• Genzyme Wins Restrictions On Generic Arthritis Drug Price
• Abbott Gets Claim Cut From Baby Formula Bugs Suit
• A Model For Olympus Shareholder Litigation
• J&J To Pay $1B To Settle Risperdal Civil Claims: Report
• Whirlpool Latest Target In Navy Encryption Patent Blitz
• Kaye Scholer Nabs Ex-Frommer Lawrence IP Pro
• Takeda, Watson Sue Mylan Over Generic Actoplus Met XR
• Scottish Equity Partners Closes New $310M Fund
• The Latest On Off-Label Responses
• Actavis Pays $118M To Settle Drug Pricing Claims
• FDA Restricts Antibiotic Use In Food Animals
• Ex-Cephalon GC Joins Morgan Lewis Litigation Group
• Fired Wyeth Employee Spoke Up Too Late: 2nd Circ.
• Pfizer Unit's Skelaxin Pay-For-Delay Deal Illegal: Suit
• FDA Orders Bard, Others To Study Surgical Mesh Implants
• ITC Denies Sanctions Bid In NuvaRing Patent Row
• Pfizer Must Pay $45M In Menopause Drug Suits: Pa. Court
• Abbott Drops Patent Claims Over Teva's Generic Simcor
• DOJ's Emphasis On FCA Cases In 2011
• J&J Investors Renew Push For CEO Liability In Recalls
• Ex-McKesson Worker Files Pay, Seating Class Action
• Reed Smith Reps Essex In $118M Biologics Deal
• FDA Seeks To Streamline Medical Device Approvals
• 9th Circ. Puts Lid On Actimmune Marketing Action
• Spire Settles With Catheter Co. Over Recall, Deal Bungle
• AstraZeneca's Symbicort Inhaler Triggers Patent Suit
• Fed. Circ. Backs $5M Cordis Award In Stent Patent Suit
• DC Circ. Snuffs Out Suit Over FDA's Ear Candle Warnings
• Varian Found To Infringe University's Radiation Patent
• Regeneron Strikes Deal With Genentech To Market Eylea
• Merck Canada Sues To Block Mylan's Generic Singulair
• Black & Decker, Others To Sweep Up RI Waste Site
• Competition Cases To Watch In 2012
• Product Liability Regulation To Watch In 2012
• Trends In M&A In 2012
• IP Cases To Watch In 2012
• Product Liability Cases To Watch In 2012
• Employment Cases To Watch In 2012